Resources Repository
-
ArticlePublication 2022Estimated Transmission Outcomes and Costs of SARS-CoV-2 Diagnostic Testing, Screening, and Surveillance Strategies Among a Simulated Population of Primary School Students
In the wake of the COVID-19 pandemic's significant educational disruptions, the U.S. government allocated $10 …
In the wake of the COVID-19 pandemic's significant educational disruptions, the U.S. government allocated $10 billion in March 2021 for testing in schools. The study aimed to analyze the costs and benefits of different COVID-19 testing strategies, particularly focusing on full-time, in-person elementary and middle school education. Utilizing an updated agent-based network model, the study simulated transmission scenarios in schools, considering various testing strategies ranging from diagnostic testing (test-to-stay) to reduce symptom-based isolations, routine screening…
Mathematical Models | Cost-Effectiveness Analysis | North America | Infectious Diseases | Test Performance | Clinical Care | Health/Medicine | Science/Technology -
ArticlePublication 2022Early HPV Natural History Transitions
Microsimulation models used to evaluate the cost-effectiveness of novel cervical cancer screening technologies rely on …
Microsimulation models used to evaluate the cost-effectiveness of novel cervical cancer screening technologies rely on accurate transition risks for human papillomavirus (HPV) infection, persistence (or absence of HPV clearance), progression to precancerous lesions, and invasion. To inform the refinement of such models, we compared the early natural history of HPV types using prospective data from immunocompetent women in the Guanacaste Natural History Study, the ASCUS-LSIL Triage Study, and the Costa Rica HPV Vaccine Trial. We…
Mathematical Models | Cost-Effectiveness Analysis | North America | Infectious Diseases | Microsimulation | Latin America & Caribbean -
ToolInteractive, Teaching Resource 2020RAND Critical Care Surge Response Tool
This Excel-based model allows decisionmakers at all levels (i.e., hospitals, health care systems, states, regions) …
This Excel-based model allows decisionmakers at all levels (i.e., hospitals, health care systems, states, regions) to examine the current critical care capacity in the nation’s hospitals and rapidly explore strategies for increasing capacity to provide care for the sickest COVID-19 patients. The tool was developed by the RAND Corporation in response to the 2020 COVID-19 pandemic. Model input parameters to the Excel spreadsheet include baseline number of beds, critical care doctors and nurses, respiratory therapists,…
Mathematical Models | Operations Research | North America | Infectious Diseases | Priority Setting/Ethics | Health/Medicine | Professional | Policy Translation -
Resource PackPublication, Teaching Resource 2017Resource Pack: CEA Herpes Zoster Vaccine
This resource pack on the cost-effectiveness of herpes zoster vaccination was curated to support Dr. …
This resource pack on the cost-effectiveness of herpes zoster vaccination was curated to support Dr. Lisa Prosser's seminar on November 9, 2017 at the Center for Health Decision Science. Dr. Prosser discussed an economic evaluation of vaccination against herpes zoster. Herpes zoster—more commonly known as shingles—presents a major burden for older Americans but, until recently, the only available vaccine (Zoster Vaccine Live, ZVL) was relatively ineffective past 10 years. A recently approved vaccine–herpes zoster subunit…
Mathematical Models | Cost-Effectiveness Analysis | North America | Infectious Diseases | Preferences/Values | Costing Methods | Health Outcomes | Clinical Care | Culture/Society | Health/Medicine | Science/Technology | Europe -
ArticlePublication 2022Modeling the Effectiveness of Healthcare Personnel Reactive Testing and Screening for the SARS-Cov-2 Omicron Variant within Nursing Homes
The Omicron variant of SARS-CoV-2 has been hypothesized to exhibit faster clearance (time from peak …
The Omicron variant of SARS-CoV-2 has been hypothesized to exhibit faster clearance (time from peak viral concentration to clearance of acute infection), may be less detectable by antigen tests (decreased sensitivity), and may be more likely to evade immunity conferred by past infection or vaccination) compared to prior variants. This calls for a reassessment of strategies to prevent its spread, especially in vulnerable settings like nursing homes. Using a model that tracks viral shedding patterns,…
Mathematical Models | North America | Infectious Diseases | Test Performance | Health/Medicine -
ArticlePublication 2023Benefits and Costs of COVID-19 Vaccine Mandates
Written mid-pandemic, this article evaluates the direct costs and health benefits of requiring COVID-19 vaccinations …
Written mid-pandemic, this article evaluates the direct costs and health benefits of requiring COVID-19 vaccinations for U.S. federal employees and healthcare and private sector workers. These mandates were controversial and some were halted by litigation. If they had been implemented as intended, the net benefits would depend on the course of the pandemic. If a more transmissible variant (such as Omicron) emerges, the net benefits may be large. If the pandemic instead fades, the benefits…
Mathematical Models | North America | Infectious Diseases | State-Transition | Benefit-Cost Analysis | Policy/Regulation | Business/Industry | Economics/Finance | Government/Law | Health/Medicine -
ArticlePublication 2022COVID-19 Response: The Need for Economic Evaluation
COVID-19-related policies are fraught with trade-offs. Many of these trade-offs involve dimensions that can be …
COVID-19-related policies are fraught with trade-offs. Many of these trade-offs involve dimensions that can be quantitatively weighed using economic evaluation, such as those between health and cost outcomes. Other types of dimensions, such as those involving equity or autonomy, can be harder to quantify but should be considered in a comprehensive health policy decision-making context nonetheless. The authors of this New England Journal of Medicine Perspectives article outline how methods of economic evaluation and decision…
Cost-Effectiveness Analysis | North America | Infectious Diseases | Priority Setting/Ethics | Benefit-Cost Analysis | Policy/Regulation | Economics/Finance | Health/Medicine | Global -
ReviewPublication 2022Systematic Review of Economic Evaluations of COVID-19 Interventions: Non-Health Impacts and Distributional Issues
The authors conducted a systematic review of economic evaluations of COVID-19 interventions and assessed whether …
The authors conducted a systematic review of economic evaluations of COVID-19 interventions and assessed whether they incorporated non-health impacts and distributional concerns. Among the 70 articles included, more than half (56%) included at least one non-health impact, although only 21% incorporated non-economic consequences. Only 17% examined subgroups of interest. The median ICER for the entire sample was $67,000/quality-adjusted life-year (QALY) (interquartile range [IQR] $9000-$893,000/QALY). Interventions including a pharmaceutical component yielded a median ICER of $93,000/QALY (IQR…
Cost-Effectiveness Analysis | North America | Infectious Diseases | Evidence Synthesis | Social Determinants | Culture/Society | Economics/Finance | Health/Medicine -
ArticlePublication 2018Should We Treat Acute Hepatitis C? A Decision and Cost-Effectiveness Analysis
This study examines the potential benefits of treating acute hepatitis C virus (HCV) infection compared …
This study examines the potential benefits of treating acute hepatitis C virus (HCV) infection compared to deferring treatment until the chronic phase, utilizing a microsimulation model. By projecting long-term outcomes such as quality-adjusted life years (QALYs) and costs, the analysis evaluates the cost-effectiveness of initiating therapy during the acute phase. Results indicate that treating acute HCV increases QALYs by 0.02 and costs by $483 per patient not at risk of transmitting HCV, yielding an incremental…
Cost-Effectiveness Analysis | North America | Infectious Diseases | Microsimulation | Decision Analysis | Chronic Disease/Risk | Health/Medicine